Three-fold rise in gabapentinoid scripts

A study using UK data suggests that gabapentinoid prescribing has tripled since 2007, with more than half the use off-label.

The rate of new scripts for gabapentin rose 2.95 fold from 230 per 100,000 patients per year in 2007 to 679 per 100,000 in 2017. Scripts for pregabalin rose by a similar amount (rate ratio [RR] 2.96) from 128 to 379 per 100,000 patients per year over the same time.

The proportion of patients who received a co-prescription for benzodiazepines, opioids or both also rose about three-fold between 2007 and 2017, from 56.4 to 148.1 per 100,000 patients per year for gabapentin (RR 2.62) and from 28.7 to 91.2 for pregabalin (RR 3.18). During 2017, 21.8 and 24.1 per cent of patients newly treated with gabapentin and pregabalin respectively received a concomitant prescription, usually for opioids.

The rate of off-label prescriptions rose from 58.7 per 100,000 patients per year in 2007 to 216.0 per 100,000 in 2017 for gabapentin (RR 3.68) and from 34.7 to 117.8 for pregabalin (RR 3.40). During 2017, 52.0 and 54.8 per cent of prescriptions for gabapentin and pregabalin respectively with an identified indication were off-label. Of these, 80.4 and 58.3 per cent respectively were for non-neuropathic pain.

“Given the safety concerns of gabapentinoids and the lack of robust evidence supporting their efficacy in cases of non-neuropathic pain, caution is necessary when prescribing gabapentinoids, especially among patients also prescribed opioids,” the authors concluded.

Recommended

Gabitril shortages to last until end of October

RPS warns Boris Johnson of no deal flu threat




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.